Seven Eight Capital, LP Halozyme Therapeutics, Inc. Transaction History

Seven Eight Capital, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$40.06 - $59.44 $880,438 - $1.31 Million	-21,978 Reduced 80.04%	5,481 $311,000
Q3 2022 Nov 10, 2022	BUY	$38.53 - $51.78 $559,532 - $751,949	14,522 Added 112.25%	27,459 $1.09 Million
Q2 2022 Aug 04, 2022	BUY	$37.35 - $48.3 $483,196 - $624,857	12,937 New	12,937 $569,000
Q4 2021 Feb 14, 2022	SELL	$31.82 - $40.75 $495,310 - $634,314	-15,566 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$38.47 - $46.42 $598,824 - $722,573	15,566 New	15,566 $633,000
Q2 2021 Aug 13, 2021	SELL	$38.84 - $51.31 $184,062 - $243,158	-4,739 Closed	0 $0
Q4 2020 Feb 09, 2021	SELL	$25.81 - $43.62 $190,994 - $322,788	-7,400 Reduced 60.96%	4,739 $202,000
Q3 2020 Nov 16, 2020	BUY	$25.74 - $29.63 $101,492 - $116,831	3,943 Added 48.11%	12,139 $319,000
Q2 2020 Aug 06, 2020	BUY	$16.25 - $26.81 $133,185 - $219,734	8,196 New	8,196 $220,000

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.